It was another busy week for Australia's top brokers. This has led to the release of a number of broker notes.
Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone:
Image source: Getty Images
GQG Partners Inc (ASX: GQG)
According to a note out of Macquarie, its analysts have retained their outperform rating on this fund manager's shares with a trimmed price target of $2.64. This follows the release of a funds under management (FUM) update from GQG which revealed a month on month decline in FUM. This was due partly to a $1 billion single institutional client outflow. And with GQG's portfolios remaining defensively positioned, resulting in all strategies underperforming their respective benchmarks this year, the broker fears that it could be a headwind for future net flows. However, it feels that at under 8x forward earnings and with a double-digit forecast dividend yield, the market is being too negative on the company and thinks its shares are dirt cheap. The GQG Partners share price ended the week at $1.78.
Life360 Inc. (ASX: 360)
A note out of Bell Potter reveals that its analysts have retained their buy rating on this location technology company's shares with an improved price target of $47.50. This follows the release of a stronger than expected second quarter update last week from Life360. In addition, the broker was pleased to see management lift its earnings guidance for FY 2026. And looking ahead, it suspects that the company could upgrade its guidance again when it releases its third quarter update later this year. This has seen Bell Potter increase its estimates and the multiples that it values its shares on. The Life360 share price was fetching $43.34 at Friday's close.
Pro Medicus Ltd (ASX: PME)
Analysts at Morgan Stanley have retained their overweight rating on this health imaging technology company's shares with an improved price target of $350.00. According to the note, the broker was very impressed with the company's FY 2025 results last week. It highlights that Pro Medicus' performance during the 12 months was better than it was expecting. It also notes that its sales pipeline and contract wins indicate that growth in FY 2026 is likely to be even better than forecast. As a result, it has lifted its earnings forecasts for the coming years and its valuation accordingly. The Pro Medicus share price was trading $313.50 at the end of the week.
